Adjuvant and post-surgical treatment in endometrial cancer

Tung, Hsiu-Jung; Huang, Huei-Jean; Lai, Chyong-Huey

doi:10.1016/j.bpobgyn.2021.06.002

Cited by 22 publications

(28 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most endometrial cancers are adenocarcinomas [ 3 ]. It is the sixth most common malignancy in women worldwide and the fourth most common cancer in developed countries [ 4 , 5 , 6 , 7 , 8 , 9 , 10 ]. According to current data available for 2020, there were 417,367 new cases of EC and 97,370 deaths caused by EC [ 8 , 11 ].…”

Section: Endometrial Cancermentioning

confidence: 99%

“…It is the sixth most common malignancy in women worldwide and the fourth most common cancer in developed countries [ 4 , 5 , 6 , 7 , 8 , 9 , 10 ]. According to current data available for 2020, there were 417,367 new cases of EC and 97,370 deaths caused by EC [ 8 , 11 ]. The rates of EC incidence increased over time, especially in high-income countries [ 6 , 8 , 12 , 13 ].…”

Section: Endometrial Cancermentioning

confidence: 99%

“…According to current data available for 2020, there were 417,367 new cases of EC and 97,370 deaths caused by EC [ 8 , 11 ]. The rates of EC incidence increased over time, especially in high-income countries [ 6 , 8 , 12 , 13 ]. At the time of diagnosis, more than 67% of patients have a localized disease at diagnosis, while 20% have regional spread, and 9% distant metastasis [ 8 , 13 , 14 ].…”

Section: Endometrial Cancermentioning

confidence: 99%

“…The rates of EC incidence increased over time, especially in high-income countries [ 6 , 8 , 12 , 13 ]. At the time of diagnosis, more than 67% of patients have a localized disease at diagnosis, while 20% have regional spread, and 9% distant metastasis [ 8 , 13 , 14 ]. EC commonly affects peri- and postmenopausal women [ 15 ], and only 5% of women are diagnosed with the disease before the age of 40 years [ 16 ].…”

Section: Endometrial Cancermentioning

confidence: 99%

“…When a diagnosis of EC is established, the disease is localized in 67% of patients, while 20% of women will have regional and 9% distant metastasis [ 8 ]. Management of EC comprises total hysterectomy with bilateral salpingo-oophorectomy and pelvic and para-aortic lymph node dissection/biopsy [ 8 , 70 , 72 , 75 , 76 , 77 ]. However, because EC is increasingly affecting younger women, this approach is not appropriate for reproductive-age patients.…”

Section: Management Of Endometrial Cancermentioning

confidence: 99%

See 4 more Smart Citations

Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients

Aimagambetova

Terzić

Laganà

et al. 2021

JCM

View full text Add to dashboard Cite

Incidence of endometrial cancer (EC) has been increasing in recent years, especially in high-income countries. The disease commonly affects peri- and postmenopausal women; however, about 5% of women are diagnosed with EC in their reproductive age. Due to both the increasing incidence of EC among reproductive age women and trends to delayed childbearing, fertility-sparing treatment for young patients with EC has become extremely important for researchers and practitioners. Because the classic treatment with total hysterectomy and bilateral saplingo-oophorectomy is not an appropriate approach for young women demanding fertility preservation, several fertility-sparing options have been developed and summarized in this review. Utilization of different medications and their combination (progestagens, gonadotropin releasing hormones analogues, and metformin in different formulations) are tested and found as efficient for fertility-sparing treatment. New minimally invasive surgical techniques, combined with progestagens, are also confirmed as valuable. There are many novel conservative and surgical treatment approaches under investigation. Assuming that molecular biomarkers can be both diagnostic and prognostic to assist in prediction of response to a certain therapy, prognostic risk groups’ stratification along with specific biomarkers’ identification will ensure low recurrence and decrease mortality rates in young women with EC.

show abstract

Section: Endometrial Cancermentioning

confidence: 99%

Section: Endometrial Cancermentioning

confidence: 99%

Section: Endometrial Cancermentioning

confidence: 99%

Section: Endometrial Cancermentioning

confidence: 99%

Section: Management Of Endometrial Cancermentioning

confidence: 99%

See 3 more Smart Citations

Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients

Aimagambetova

Terzić

Laganà

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

Gel/hydrogel‐based in situ biomaterial platforms for cancer postoperative treatment and recovery

et al. 2023

View full text Add to dashboard Cite

Tumor surgical resection is the major strategy for cancer treatment. Meanwhile, perioperative treatment especially the postoperative adjuvant anticancer strategies play essential roles in satisfying therapeutic results and rapid recovery. Postoperative tumor recurrence, metastasis, bleeding, inter‐tissue adhesion, infection, and delayed wound healing are vital risks that could lead to poor prognosis or even treatment failure. Therefore, methods targeting these postoperative complications are in desperate need. In situ biomaterial‐based drug delivery platforms are promising candidates for postoperative treatment and recovery, resulting from their excellent properties including good biocompatibility, adaptive shape, limited systemic effect, designable function, and easy drug loading. In this review, we focus on introducing the gel/hydrogel‐based in situ biomaterial platforms involving their properties, advantages, and synthesis procedures. Based on the loaded contents in the gel/hydrogel such as anticancer drugs, immunologic agents, cell components, and multifunctional nanoparticles, we further discuss the applications of the in situ platforms for postoperative tumor recurrence and metastasis inhibition. Finally, other functions aiming at fast postoperative recovery were introduced, including hemostasis, antibacterial infection, adhesion prevention, tissue repair, and wound healing. In conclusion, gel/hydrogel is a developing and promising platform for postoperative treatment, exhibiting gratifying therapeutic effects and inconspicuous toxicity to normal tissues, which deserves further research and exploration.

show abstract

Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1

Wang,

Liu

et al. 2023

Phytomedicine

View full text Add to dashboard Cite

Adjuvant and post-surgical treatment in endometrial cancer

Cited by 22 publications

References 46 publications

Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients

Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients

Gel/hydrogel‐based in situ biomaterial platforms for cancer postoperative treatment and recovery

Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1

Contact Info

Product

Resources

About